ArticleInflammopharmacology2026
Therapeutic efficacy of Curcuma longa leaf extract in experimental models of arthritis.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arthritis is a chronic inflammatory disorder that affects millions worldwide, leading to persistent joint pain, stiffness, swelling, and impaired mobility. Although conventional therapies are effective in symptom management, their long-term use is often limited by adverse effects and poor adherence. This study investigated the anti-arthritic potential of Curcuma longa leaf extract using in vivo arthritic rat models, liquid chromatography-mass spectrometry (LC-MS), Fourier transform infrared (FTIR) spectroscopy, and in silico molecular docking approaches. LC-MS analysis identified several bioactive compounds, including curcumin, turmerones, squalene, n-hexadecanoic acid, and 9-octadecenoic acid, which are known for their anti-inflammatory, antioxidant, immunomodulatory, and analgesic properties. FTIR spectroscopy confirmed the presence of functional groups such as hydroxyl (-OH), amide (-NH), alkane (-CH), and amine (-NH), supporting the bioactivity of the extract. Molecular docking studies revealed strong binding affinities of key compounds, including 1 H-Indole, 1-methyl-2-phenyl, turmerone, and curcumin-toward major inflammatory targets, tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), with binding energies comparable to the standard anti-inflammatory drug indomethacin. In vivo evaluation demonstrated significant attenuation of arthritis-associated biomarkers, including reductions in pro-inflammatory cytokines (TNF-α and IL-6), C-reactive protein, adenosine deaminase activity, oxidative stress markers, leukocyte counts, joint swelling, and pain-related behaviors, alongside normalization of bone mineral and uric acid levels. Collectively, these findings indicate that C. longa leaf extract exerts multi-targeted anti-arthritic effects through modulation of inflammatory, oxidative, immune, and pain pathways, supporting its potential as a complementary therapeutic agent for arthritis management and warranting further clinical investigation.
Indexed as
Identifiers
41784928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.